WB result of Anti-Human IL-1β Monoclonal Antibody (Canakinumab)
Primary antibody: Anti-Human IL-1β Monoclonal Antibody (Canakinumab) at 1/1000 dilution
Lane 1: IL-1β Protein, Rat 1 µg
Lane 2: IL-1β Protein, Mouse 1 µg
Lane 3: IL-1β Protein, Human 1 µg
Secondary antibody: Goat Anti- human IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 31 kDa
Observed MW: 17 kDa
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | IL-1 beta |
| Synonyms | Interleukin-1 beta; IL-1 beta; Catabolin; IL1F2; IL1B |
| Accession | P01584 |
| Clone Number | S-4606 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1 |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Dilution
| application | dilution | species |
| WB | Hu |
Background
Interleukin-1 beta (IL-1β) is a pro-inflammatory cytokine that plays a crucial role in the immune response. It is produced by various cell types, including macrophages and monocytes, in response to infections or tissue injury. IL-1β helps to initiate and amplify the inflammatory response by promoting the expression of other inflammatory mediators and recruiting immune cells to the site of infection or damage. It also has effects on a wide range of physiological processes, such as fever induction, modulation of the hypothalamic-pituitary-adrenal axis, and regulation of metabolism. Dysregulation of IL-1β has been implicated in numerous chronic inflammatory diseases, like rheumatoid arthritis and inflammatory bowel disease, making it an important target for therapeutic interventions.
Picture
Picture
Western Blot
